Supernus Pharmaceuticals (SUPN) Change in Accured Expenses (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Change in Accured Expenses data on file, last reported at $49000.0 in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $49000.0, down 98.76% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.5 million (up 45.5% YoY), and the FY2025 annual result was -$7.6 million, up 49.33% from the prior year.
• Change in Accured Expenses retreated to $49000.0 in Q1 2026 per SUPN's latest filing, from $16.5 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $17.6 million in Q3 2024 and troughed at -$44.9 million in Q4 2022.
• A 5-year average of -$2.3 million and a median of $5.6 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses sank 464.43% in 2022, then soared 194.98% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$44.9 million in 2022, then soared by 81.74% to -$8.2 million in 2023, then slumped by 264.25% to -$29.9 million in 2024, then soared by 155.14% to $16.5 million in 2025, then slumped by 99.7% to $49000.0 in 2026.
• Business Quant data shows SUPN's Change in Accured Expenses at $49000.0 in Q1 2026, $16.5 million in Q4 2025, and -$36.3 million in Q3 2025.